Release date: 8th November 2005
Embargoed until: 07:00
CLS HOLDINGS PLC ('CLS')
ANNOUNCES ITS FIRST ACQUISITION OF
OFFICES IN HAMBURG, GERMANY
The Board of CLS is delighted to announce its intention to add Germany to its
core property investment regions, which currently consist of UK, Sweden and
France. In line with this strategy to build a portfolio in Germany, the Company
is pleased to report the acquisition of a building in West Hamburg at a price
of €3.6 million (£2.45 million) inclusive of all costs.
The property, known as Frohbösestrasse 12, was constructed in April 2005 and
comprises 1,993 sq m (21,453 sq ft) of offices together with 19 car parking
spaces. It has the benefit of a new lease with Scope International Life Science
Hamburg AG, a pharmaceutical research company, for a term of 15 years without a
break at an annual rent of €248,835 (£169,630). The rent will be adjusted by
reference to the German retail price index.
The return on equity on the completed loan facility of €2.68 million (£1.82
million) is 22.8%, whilst the cash return on equity is 14.4%.
This acquisition represents CLS' first investment in the German market for many
years (having owned a property in Düsseldorf for many years). CLS intends to
make further selective acquisitions in Germany, where the Company has
identified an opportunity to benefit from the attractive yields and high
returns on equity on a geared basis.
Executive Chairman, Sten Mortstedt, commented:
'I am particularly excited by the opportunities that Germany presents as an
additional core region in our portfolio. This first venture into Hamburg
provides an excellent example of the quality of returns that we stand to gain
from this market.'
-ends-
For further information, please contact:
Sten Mortstedt, Executive Chairman
Tom Thomson, Chief Executive & Vice Chairman
Dan Bäverstam, Chief Financial Officer
Steven Board, Chief Operating Officer
CLS Holdings plc
www.clsholdings.com
Tel. +44 (0)20 7582 7766
Adam Reynolds/Ben Simons
Hansard Communications
Tel. 44 (0)20 7245 1100
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.